News und Analysen
EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
Sonova further extends offering of Sennheiser-branded hearing solutions with All-Day Clear
Sonova further extends offering of Sennheiser-branded
hearing solutions with All-Day Clear
Annual General Shareholders’ Meeting 2023: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2023:
Sonova shareholders approve all motions of the Board of Directors
Financial year 2022/23: Sonova delivers solid results and preserves profit growth
Financial year 2022/23: Sonova delivers solid results
and preserves profit growth
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
Katya Kruglova to join Sonova’s Management Board as GVP Human Resources & Communications
EQS-Adhoc: BB Biotech AG publishes its 2022 annual report
EQS-Adhoc: BB Biotech AG publishes its 2022 annual report
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-Adhoc: BB Biotech AG closes the 2022 fiscal year with a loss
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
EQS-News: BB BIOTECH AG: Divergent biotech equity markets mirror value over growth theme in 2022 – Proposed dividend of CHF 2.85
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Sonova launches Conversation Clear Plus earbuds, expanding into the new category of early entry hearing solutions
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
EQS-News: BB BIOTECH AG: Molecular strike force for the immune system
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that
First half results 2022/23: Growth in all regions and further progress on strategic initiatives
First half results 2022/23:
Growth in all regions and further progress on strategic initiatives
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation
EQS-News: BB BIOTECH AG: US drug pricing legislation drives biotech business to adapt for further innovation
Approval of extension of exemptions from SIX disclosure and publicity obligations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (Vifor) announced today that by decision dated October 19, 2022, SIX Exchange Regulation AG (SER) has approved an
Approval of delisting of Vifor Pharma AG's registered shares
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma AG (SWX:VIFN) (Vifor) announced today that Vifor has received approval for the delisting of the totality of Vifor's
Sonova Investor & Analyst Day 2022: Leading innovation and further expanding our reach
Sonova Investor & Analyst Day 2022:
Leading innovation and further expanding our reach